A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis-Reference-Cited by-同舟云学术

A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis

Published:2024-05-23 Issue:6 Volume:23 Page:687-714
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Sen Rouhin¹²,Riofrio Maria¹,Singh Jasvinder A.¹²³

Affiliation:

1. Division of Clinical Immunology and Rheumatology, The University of Alabama Birmingham, Birmingham, AL, USA

2. Medicine/Rheumatology Birmingham Veterans Affairs Medical Center (VAMC), Birmingham, AL, USA

3. Department of Epidemiology, UAB School of Public Health, Birmingham, AL, USA

Funder

the National Institutes of Arthritis, Musculoskeletal and Skin Diseases

Department of Veterans Affairs

the Patient Centered Outcomes Research Institute

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2348575

Reference174 articles.

1. Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model

2. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study;Lampropoulos CE;Clin Exp Rheumatol,2015

3. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0

4. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

5. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality-by-Design (QbD) Assisted Synthesis of Nanoparticle for Efficient Loading, Stabilization, and Intracellular Delivery of Bioactive for the Treatment of Arthritis;Indian Journal of Microbiology;2024-07-29